Researchers set out to compare the time until the next treatment in patients with chronic lymphocytic leukemia who are treated with single-agent ibrutinib at a sustained dose of 420 mg/day vs patients who...
Researchers set out to compare the time until the next treatment in patients with chronic lymphocytic leukemia who are treated with single-agent ibrutinib at a sustained dose of 420 mg/day vs patients who...
Researchers conducted a retrospective analysis of 469 patients with HR+/HER2- metastatic breast cancer and cardiovascular diseases treated with palbociclib plus aromatase inhibitors or aromatase inhibitors...
Researchers conducted a retrospective analysis of 469 patients with HR+/HER2- metastatic breast cancer and cardiovascular diseases treated with palbociclib plus aromatase inhibitors or aromatase inhibitors...
Researchers conducted a retrospective analysis of 469 patients with HR+/HER2- metastatic breast cancer and cardiovascular diseases treated with palbociclib plus aromatase inhibitors or aromatase inhibitors...
Researchers conducted a retrospective analysis of 469 patients with HR+/HER2- metastatic breast cancer and cardiovascular diseases treated with palbociclib plus aromatase inhibitors or aromatase inhibitors...
Researchers conducted a retrospective analysis of 469 patients with HR+/HER2- metastatic breast cancer and cardiovascular diseases treated with palbociclib plus aromatase inhibitors or aromatase inhibitors...
Researchers conducted a retrospective analysis of 469 patients with HR+/HER2- metastatic breast cancer and cardiovascular diseases treated with palbociclib plus aromatase inhibitors or aromatase inhibitors...
Researchers conducted a retrospective analysis of 469 patients with HR+/HER2- metastatic breast cancer and cardiovascular diseases treated with palbociclib plus aromatase inhibitors or aromatase inhibitors...
Leading experts in the fields of cardiovascular and family medicine describe the risk factors associated with cardiovascular disease, review the strategies designed to mitigate the risk factors associated...
